Signifier® Medical Technologies Wins IDEA Design Award 2020 for eXciteOSA®, the World’s First, Daytime Treatment Device That Tackles the Root Cause of Sleep-Disordered Breathing
London, United Kingdom
September 17, 2020
Signifier® Medical Technologies, an innovator in the sleep-disordered breathing market is delighted to announce that it has been awarded a bronze IDEA award by the prestigious Industrial Designers Society of America (IDSA) in the “Medical & Health” category, for its novel medical device, eXciteOSA® – designed for patients with sleep-disordered breathing conditions.
Founded in 1965, Industrial Designers Society of America is one of the oldest and largest industrial design associations in existence, with 2020 marking the 40th anniversary of the International Design Excellence Awards (IDEA).
Originally founded to recognize exceptional achievement in industrial design, the program has since grown with thousands of entries submitted by design teams across the globe, making IDEA one of the largest and most widely anticipated annual awards programs in the world.
Professor Dr Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham, was keenly aware of the fact that many of his patients were struggling with conventional treatment options for their sleep-disordered breathing (SDB) conditions. Based on an understanding of this significant unmet need and working with a talented multidisciplinary team, he created the world’s first, daytime treatment device that tackles the root cause of SDB.
eXciteOSA® works by improving tongue muscle endurance and responsiveness preventing upper airway collapse during sleep. Clinically significant results have been observed, when used for 20 minutes, once a day, for 6 weeks. 2-4
More information about the eXciteOSA IDSA award can be found here: https://www.idsa.org/awards/idea/medical-health/snoozeal
Images of the eXciteOSA® device are available upon request to email@example.com
About Snoring and OSA
Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.1
Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.
About Signifier Medical Technologies
Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.2-4
About International Designers Society of America
Founded in 1965, IDSA is one of the oldest and largest membership associations for industrial design professionals with thousands of members in Student Chapters, Professional Chapters and Special Interest Sections in the United States and internationally. IDSA sponsors IDEA®, the world’s most prestigious and rigorous design competition. The Society hosts events including an annual International Design Conference, five District Design Conferences and a Medical Design Conference, bringing together some of the biggest names and brightest minds in industrial design and related fields.
- White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
- Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
- Sama A, et al. Daytime Intraoral Neurostimulation with eXciteOSA® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
- Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period
For media enquiries:
+44 (0) 207 096 0586